Fairvalue-Calculator Fairvalue-Calculator
EN DE

MiMedx Group (MDXG) Fair Value & Analysis

Healthcare · US · Market cap $547M

Price$3.83
Fair Value$7.18
Upside+87.5%
Quality95/100
Evidence: High Range $5.38 – $8.97

Fair value as of: Jun 25, 2026

Analysis

MiMedx Group (MDXG) currently trades at $3.83, while our model-based Fair Value estimate is $7.18 — implying the stock looks roughly 87.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.

About the company

MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company processes the human placental tissues membrane, and umbilical cord and the placental disc utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins, including cytokines, chemokines, and growth factors. Its patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. The company's wound care products include EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets for use as protective barriers that enables a healthcare provider to select an appropriate size graft based on the size of the wound to reduce product waste. Its surgical and other product offerings consist of AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT for applications in a variety of appl…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is MiMedx Group (MDXG) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $7.18 versus a price of $3.83 — about +87% (undervalued). Model-based estimate, not financial advice.
What is the fair value of MDXG?
Our 21-model fair value for MiMedx Group is $7.18 (as of Jun 25, 2026), built from audited fundamentals. The current price is $3.83.
What is the quality score of MDXG?
MiMedx Group has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.